Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Immunoblastic Lymphadenopathy × etoposide phosphate × Clear all

Phase

Status

Unknown 1 Terminated 1 Suspended 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma 1 Immunoblastic Lymphadenopathy 1 Enteropathy-Associated T-Cell Lymphoma 1

Interventions

tazemetostat 1 etoposide phosphate 1 brincidofovir 1 Vincristine 1 Prednisone 1 Prednisolone 1 Melphalan 1 Etoposide 1 Doxorubicin 1 Cytarabine 1 Cyclophosphamide 1 Carmustine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692452 2026-01-07

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡